Clinical Trial Search

Primary: Mean Self-reported Adherence Score (%) Over a One-month Recall — 97.5; 98.2 percentage of adherence score — p=0.52

Primary: AIDS Clinical Trials Group (ACTG) 3-day Recall Measure of Doses Taken — 72.89; 75.46; 74.86; 77.33 percent with 100% adherence — p=0.12

Primary: Adherence Measured by Sensor by Percentage of Prescribed Medications Taken — 87.5 percentage of prescribed medication

Primary: Number of Participants ≥90% Adherent to Antiretroviral Medication Based on MEMS Cap Openings — 9; 5 Participants — p=0.32

Primary: Mean Adherence, as Measured by Electronic Drug Monitors (EDM) — 96.5; 84.5; 96.4; 84.1 percentage of doses taken on time

Primary: Change in Tenofovir Diphosphate (TFV-DP) Drug Levels — 1230; 1108; 1887; 1084 fmol/punch — p=0.070

Primary: Rate of Medication Adherence — 2; 1 Participants

Primary: Medication Adherence as Assessed by the Medication Event Monitoring System (MEMS) Cap — 52.2; 27.2 percentage of participants

Primary: Medication Adherence — 77.96; 80.13; 64.87; 76.13 Percentage of doses taken — p=.005

Primary: Proportion Adherent to ARV and Psychotropic Medication by Electronic Monitoring System (MEMS) — 90.3; 90.0; 83.9; 90.0 percentage of taken doses — p=0.95

Primary: Depression From (1) Clinician-Administered MADRS Measure, and (2) Participant Self-Report Ratings With BDI-1a — 17.8; 19.2; 19.7; 17.7 Units on a scale

Primary: Number of Participants in Each Condition With Optimal ART Adherence — 27; 29 participants

Primary: Confirmed Virologic Failure at or Prior to Week 48 — 95; 105; 34; 23 participants — p=0.133

Primary: Raw Count of Number of Days of Medication Nonadherence — 28 % of nonadherence days

Primary: Antiretroviral Therapy (ART) Adherence (Self-reported 3-day Recall Measure) — 142; 139; 6; 12 participants

Primary: Change in Medication Adherence as Measured by the Adherence to Refills and Medications Scale (ARMS) — -4.0; -1.0 score on a scale

Primary: End-of-intervention Varenicline Adherence — 18; 16; 15 participants

Primary: Percent of Participants With Adherence at Month 6 — 91; 40 percent persistent on therapy — p=<0.05

Primary: Overall MEMS Adherence to Antiretroviral Medication — 68.0; 70.4 percentage of taken doses — p=0.68

Primary: Feasibility of the Intervention - Number of Counseling Sessions — 2.92; 1 sessions

Primary: Blood Pressure Medication Adherence — 396; 470 Participants — p=0.0103

Primary: Log10 HIV-1 Viral Load — 1.48; 1.82 Log10 copies/ml

Primary: ART Adherence at 20 Weeks as Determined by VAS, Viral Load — 57; 47; 63; 46 Participants

Primary: Feasibility of Retaining Study Participants Through the 3 Month Trial — 20; 21 Participants

Primary: Percent Medication Adherence at 3-month Follow-up Assessment — 79.02; 73.66 percent (doses taken/doses prescribed) — p=<.05

Primary: Adherence to Cabenuva Injections — 1; 17; 0; 1 Participants

Primary: Changes in HIV Medication Adherence Throughout Intervention Phase — 60.0; 28.2 percentage of days adherent to Wisepill — p=.01

Primary: Rate of Medication Adherence — 0.76; 0.79; 0.83 percentage of doses taken — p=0.78

Primary: Number of Particpatns Who Considered the Intervention Feasible and Acceptable — 20 participants

Primary: Percentage of Participants With Plasma Human Immunodeficiency Virus - Type I Ribonucleic Acid (HIV-1 RNA) Levels Less Than (<) 50 Copies/mL at Week 12 — 24.4; 20.9…